Product Description
Alitretinoin is a first generation member of the retinoid family, which also includes retinol, retinal, tretinoin, isotretinoin and acitretin. The retinoids are all related to Vitamin A. (Sourced from: https://dermnetnz.org/topics/alitretinoin)
Mechanisms of Action: RXR Agonist,RAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Bulgaria | Canada | Chile | Denmark | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Lithuania | Malta | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Alitretinoin versus cyclosporine in hand eczema | P3 |
Active, not recruiting |
Dermatitis, Atopic |
None |